This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Here's Why Merck (MRK) Stock Has Outperformed Industry YTD
by Zacks Equity Research
Strong sales of key products like Keytruda and Gardasil and positive pipeline/regulatory developments should keep Merck's (MRK) stock afloat in 2023.
Prometheus Biosciences, Inc. (RXDX) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does Prometheus Biosciences, Inc. (RXDX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Biotech ETFs Pop on M&A Resurgence
by Neena Mishra
2023 could be a year of heightened biotech dealmaking activity
Prometheus Biosciences, Inc. (RXDX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Prometheus Biosciences, Inc. (RXDX) delivered earnings and revenue surprises of 6.52% and 74.57%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Rhythm Pharmaceuticals, Inc. (RYTM) delivered earnings and revenue surprises of -29.58% and 2.71%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Merck (MRK) Beats on Q1 Earnings and Sales, Ups 2023 View
by Zacks Equity Research
Merck (MRK) beats Q1 estimates for earnings and sales. It raises its 2023 guidance. Stock rises in pre-market.
AbbVie (ABBV) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
AbbVie (ABBV) delivered earnings and revenue surprises of 0.82% and 1.17%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Pharma Stock Roundup: JNJ Beats on Q1 Earnings, MRK to Buy RXDX & Other Updates
by Kinjel Shah
J&J (JNJ) beats earnings and sales estimates for the first quarter. Merck (MRK) offers to buy Prometheus Biosciences (RXDX).
Company News for Apr 18, 2023
by Zacks Equity Research
Companies in The News Are: MTB,RXDX,NFLX,ANET,MRK
Prometheus Biosciences, Inc. (RXDX) Stock Jumps 69.7%: Will It Continue to Soar?
by Zacks Equity Research
Prometheus Biosciences, Inc. (RXDX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Prometheus (RXDX) Stock Surges 70% on Buyout Offer From Merck
by Zacks Equity Research
Prometheus (RXDX) is set to be acquired by Merck for $11 billion, adding Prometheus' lead product candidate, PRA023, to Merck's portfolio. Prometheus' stock is up 70%.
Prometheus Biosciences, Inc. (RXDX) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Prometheus Biosciences, Inc. (RXDX) delivered earnings and revenue surprises of 1.10% and 6.71%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Denali Therapeutics Inc. (DNLI) Surges 5.8%: Is This an Indication of Further Gains?
by Zacks Equity Research
Denali Therapeutics Inc. (DNLI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Wall Street Analysts Think Prometheus Biosciences, Inc. (RXDX) Could Surge 33.49%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for Prometheus Biosciences, Inc. (RXDX) points to a 33.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks Investment Ideas feature highlights: XBI, Catalyst Pharma, Prometheus Biosciences, Sage Therapeutics and IBB
by Zacks Equity Research
XBI, Catalyst Pharma, Prometheus Biosciences, Sage Therapeutics and IBB are part of the Zacks Investment Ideas article.
Biotech's Blockbuster Week: 3 Stocks to Watch
by Andrew Rocco
In a strong week for the market, biotech dominated. Today we will cover 3 promising stocks in the space.
Wall Street Analysts Believe Prometheus Biosciences, Inc. (RXDX) Could Rally 26.51%: Here's is How to Trade
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 26.5% in Prometheus Biosciences, Inc. (RXDX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Prometheus Biosciences, Inc. (RXDX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Prometheus Biosciences, Inc. (RXDX) delivered earnings and revenue surprises of -1.12% and 26.37%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
What Makes Prometheus Biosciences, Inc. (RXDX) a New Buy Stock
by Zacks Equity Research
Prometheus Biosciences, Inc. (RXDX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Prometheus Biosciences, Inc. (RXDX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Prometheus Biosciences, Inc. (RXDX) delivered earnings and revenue surprises of 6.52% and 81.29%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Xenon Pharmaceuticals (XENE) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Xenon Pharmaceuticals (XENE) delivered earnings and revenue surprises of -12.25% and 91.63%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
VBI Vaccines, Inc. (VBIV) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
VBI Vaccines, Inc. (VBIV) delivered earnings and revenue surprises of -157.14% and 50.78%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Vertex Pharmaceuticals (VRTX) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Vertex (VRTX) delivered earnings and revenue surprises of 3.45% and 3.02%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Fate Therapeutics (FATE) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Fate Therapeutics (FATE) delivered earnings and revenue surprises of 8.14% and 38.21%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Prometheus Biosciences, Inc. (RXDX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Prometheus Biosciences, Inc. (RXDX) delivered earnings and revenue surprises of -5.13% and 459.86%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?